WebFeb 3, 2024 · COMPASS Pathways plc (NASDAQ:CMPS) Q4 2024 Earnings Call Transcript. Operator: Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Conference Call. At this time, all participants ... WebFeb 27, 2024 · Compass Pathways bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New...
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript
WebOct 12, 2024 · Oct. 12, 2024, 04:09 PM Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on... WebFeb 28, 2024 · Mental healthcare biotech COMPASS Pathways reported its financial results for the fourth quarter and year-end 2024 and provided an update on recent pipeline and … galt temporary agency
Growing Psychedelic Interest Will Help Push Compass Pathways …
WebFeb 28, 2024 · For the year ended December 31st, 2024, net loss was $91.5 million, or $2.16 per share, compared with a net loss of $71.7 million, or $1.79 per share, during the same period in 2024. These results ... WebMar 13, 2024 · Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Buy’ rating and US$60 price target for COMPASS Pathways after the mental health care company adjusted the trial design for its COMP360 phase 3 program investigating psilocybin for treatment-resistant depression (TRD). “We are not making any major changes to our … WebFeb 28, 2024 · LONDON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in ... galt technology